Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-SMART: Multi-Arm Trial in Alzheimer's Disease
NCT07724132Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jul 2026
- Primary completion
- Mar 2031
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atomoxetine and liquid metformin (Aspargo Labs) in Alzheimer's disease (AD) (3 arms), sponsored by University College London. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 18 months and Amsterdam Instrumental Activities of Daily Living Questionnaire - Short Version at 18 months. Started Jul 2026; status: recruiting.
02
Drugs
atomoxetineliquid metformin (Aspargo Labs)
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07724132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724132.